Astellas’ Once-Daily Tacrolimus Again “Approvable” For Kidney Transplant Patients
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma received a second U.S. FDA "approvable" letter for use of its long-lasting immunosuppressant FK506 in kidney transplant patients, the company said March 14.
You may also be interested in...
Astellas Tacrolimus Approval Remains At Bay
Astellas Pharma has met with another snag in its attempt to win FDA approval for the once-daily version of its immunosuppressant Prograf (tacrolimus) with receipt of an FDA "approvable" letter for prophylaxis of organ rejection in liver transplant patients
Astellas Tacrolimus Approval Remains At Bay
Astellas Pharma has met with another snag in its attempt to win FDA approval for the once-daily version of its immunosuppressant Prograf (tacrolimus) with receipt of an FDA "approvable" letter for prophylaxis of organ rejection in liver transplant patients
Astellas Backed By Full Pipeline To Battle Japan Price Controls and Slow Approvals In U.S.
Astellas' user fee date for immunosuppressant Prograf MR (tacrolimus) NDA pending at the U.S. FDA has been extended for another three months, the company told a third quarter earnings call Feb.1 at its headquarters in Tokyo